

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal No. 299; Bosutinib for previously treated chronic myeloid leukaemia**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company/Sponsor</u></p> <ul style="list-style-type: none"> <li>▪ Pfizer (bosutinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• African Caribbean Leukaemia Trust (ACLT)</li> <li>• Anthony Nolan</li> <li>• Black Health Agency</li> <li>• Bloodwise</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Chronic Myeloid Leukaemia Support Group</li> <li>• Delete Blood Cancer</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Leukaemia Cancer Society</li> <li>• Leukaemia CARE</li> <li>• MacMillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Rarer Cancers Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Blood Transfusion Society</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator Companies</u></p> <ul style="list-style-type: none"> <li>• Bristol-Myers Squibb (hydroxycarbamide)</li> <li>• MSD Ltd (interferon alpha)</li> </ul> <p><u>Relevant Research Groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Haematological Malignancies Group</li> <li>• <u>Leuka</u></li> <li>• Leukaemia Busters</li> <li>• MRC Clinical Trials Unit</li> <li>• Institute of Cancer Research</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guideline Centre</li> </ul> <p><u>Associated Public Health Groups</u></p>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• British Society for Human Genetics</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Forum on Haemoglobin Disorders</li> <li>• UK Health Forum</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Doncaster CCG</li> <li>• NHS England</li> <li>• NHS Surrey Heath CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company(ies) or sponsor(s) responsible for the technology; national professional organisations; national patient/carer organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company/sponsors commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.